CSL Behring is a global leader in the plasma protein therapeutics industry. Committed to saving and improving the lives of people with rare and serious medical disorders, we research, develop, manufacture and market plasma-derived and recombinant biotherapies.
At A Glance
CSL Behring is a global leader in the plasma-protein biotherapeutics industry, providing lifesaving treatments that include recombinant biotherapies for a range of rare and serious medical disorders. CSL Behring also operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia.
10,500+ employees in
Headquartered in Boca Raton, Florida, United States
Our products are used around the world to treat coagulation disorders such as hemophilia and von Willebrand disease (VWD), primary immune deficiencies, hereditary angioedema and inherited respiratory disease, as well as neurological disorders in certain markets. We also manufacture products that are used in cardiac surgery, organ transplantation, burn treatment and to treat acquired bleeding and prevent hemolytic disease of the newborn.
At CSL Behring we are committed to the people who rely on our products. We never forget that our therapies are essential to the life and well-being of every patient. Each of us brings that sense of purpose to work every day. Our Core Values—customer focus, innovation, integrity, collaboration and superior performance—underscore our purpose and our commitment to provide the best possible therapies and services.
We continually leverage our medical and scientific expertise to develop new therapies, create new applications and innovative enhancements for our products, and identify underserved markets. We invest in emerging technologies to develop new products and improve existing therapies.
We continue to increase our investment, growing the R&D project portfolio and enhancing and expanding global capabilities where they can add the most value. CSL Behring has more than 1,000 R&D employees who serve on various global project teams to maximize individual expertise while leveraging core capabilities at each site.
CSL Behring maintains state-of-the-art manufacturing facilities that we have been expanding to keep pace with the growing demand for immunoglobulin and albumin.
We strive to ensure our manufacturing processes and facilities are state-of-the-art and can meet a growing demand for immunoglobulin and albumin. Our facilities combine advanced industrial-scale filtration technology, highly efficient separation processes and advanced formulation to generate our innovative plasma therapies.
Even the most innovative therapies are meaningless if people are not able to obtain them. CSL Behring offers a broad range of programs and services to assist patients and physicians with reimbursement support and ways to ensure access to their therapies. We also partner with patient associations to advocate for legislation that protects patient and physician choice of therapy, appropriate standards of care, appropriate reimbursement and other topics that impact the rare disease communities we serve.
CSL Behring global headquarters in King of Prussia, Pennsylvania
CSL Behring has been recognized by patient groups and the industry for its innovative lifesaving therapies. The European Organization for Rare Disorders presented its EURORDIS Award to CSL Behring for “pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions.”
The National Organization for Rare Disorders recognized CSL Behring for developing and marketing the first treatment in the United States for acute bleeding episodes in patients with congenital fibrinogen deficiency. Forbes has included CSL Behring in its Top 50 List of the world’s most innovative companies.
This corporate profile was reviewed and approved by CSL Behring.